A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Clinical trial NCT06911502 · RECRUITING
Trial details
- NCT number
- NCT06911502
- Sponsor
- Celgene
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-28
- Primary completion
- 2028-04-24
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.